SGLT2-Associated Ketoacidosis: Glucose Can Mislead

Clinical Mastery · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Glycosuria and ketosis may persist after the last dose. Treatment resolution depends on acid–base and ketone recovery, not glucose alone.

Glucose loss can coexist with ketone-related illness. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Glucose loss can coexist with ketone-related illness. Glucose leaves in urine — SGLT2 inhibition lowers glucose reabsorption; Glucose may look reassuring — A very high value is not required; Ketones can rise during illness — Assess the context and symptoms; Urgent assessment — Concerning illness needs prompt clinical evaluation. Euglycemic ketoacidosis is a distinct safety branch; use the prescribed illness and procedure plan. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Ketones despite modest glucose

SGLT2 inhibition can promote ketogenesis while urinary glucose loss limits hyperglycemia. A reassuring glucose value does not exclude dangerous ketoacidosis.

Recognize the setting

Fasting, surgery, acute illness, reduced insulin delivery, dehydration, and marked carbohydrate restriction increase concern. Type 1 diabetes presents additional risk and regulatory limitations.

Test ketones despite normal glucose

In an SGLT2 user with nausea, abdominal pain, tachypnea, or unexplained illness, check blood beta-hydroxybutyrate and acid–base status even when glucose is not markedly elevated. Stop the SGLT2 inhibitor when ketoacidosis is suspected; investigate infection, fasting, and missed insulin.

Treat urgently

Stop the implicated medication and use an appropriate supervised ketoacidosis protocol. Insulin, carbohydrate, fluid, and potassium decisions must follow the patient's evolving physiology.

Plan procedures and illness

Empagliflozin labeling calls for withholding at least 3 days before surgery or prolonged-fasting procedures when possible. Follow the actual agent label; intervals are not identical across the class. Resume only when clinically stable and eating. Do not omit necessary basal insulin simply because glucose is normal.

Avoid false reassurance

Glycosuria and ketosis may persist after the last dose. Treatment resolution depends on acid–base and ketone recovery, not glucose alone.

Supporting evidence

Continue learning